跳至主要内容
临床试验/JPRN-jRCT1051220043
JPRN-jRCT1051220043已完成未知

A prospective, randomized and endoscopist-blinded trial to evaluate comparable efficacy of a 1-L PEG and ascorbic acid with sennoside versus a 2-L PEG and ascorbic acid for bowel preparation - Senno trial

Fukuda Takashi0 个研究点目标入组 344 人开始时间: 2022年6月10日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
344

研究概览

简要总结

The 1L-PEG/AS regimen was comparable to the 2L-PEG/A regimen in terms of BP adequacy, requiring lesser BP solution volumes, with better patient tolerance.

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 <= 85age old(—)
性别
All

入选标准

  • 1) patients who were scheduled for elective colonoscopy
  • 2) patients who aged over 20 years old and under 85 years old
  • 3) patients who were able to fill in the informed consent form for participation

排除标准

  • 1) severe heart failure (NYHA class III or IV)
  • 2) severe hepatic failure (Child-Pugh C)
  • 3) active inflammatory bowel disease
  • 4) dementia
  • 5) allergy to Moviprep or sennoside
  • 6) advanced colorectal cancer
  • 7) intestinal resection
  • 8) past history of participance in this study

研究者

发起方
Fukuda Takashi

相似试验

Trial to evaluate comparable efficacy of a 1-L PEG... | 临床试验